Longevity biotech raises $100 million …
Longevity biotech raises $100 million
Juvenescence raises $100M to fund longevity assets to early readouts
Juvenescence has raised $100 million to advance multiple anti-aging programs. The U.K. company, which was co-founded by Jim Mellon, has reeled in $165 million over 18 months to establish itself at the forefront of the nascent longevity sector.